KR102930652B1 - 바이오마커로서의 무세포 뉴클레오솜의 사용 - Google Patents

바이오마커로서의 무세포 뉴클레오솜의 사용

Info

Publication number
KR102930652B1
KR102930652B1 KR1020227022609A KR20227022609A KR102930652B1 KR 102930652 B1 KR102930652 B1 KR 102930652B1 KR 1020227022609 A KR1020227022609 A KR 1020227022609A KR 20227022609 A KR20227022609 A KR 20227022609A KR 102930652 B1 KR102930652 B1 KR 102930652B1
Authority
KR
South Korea
Prior art keywords
cancer
cell
subject
histone
vascular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020227022609A
Other languages
English (en)
Korean (ko)
Other versions
KR20220110794A (ko
Inventor
제이콥 빈센트 미칼레프
헤더 윌슨-로블스
마크 에드워드 에클스턴
마리엘 찬탈 안드레 헤르조그
제이슨 브래들리 테렐
Original Assignee
벨지언 볼리션 에스알엘
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 벨지언 볼리션 에스알엘 filed Critical 벨지언 볼리션 에스알엘
Publication of KR20220110794A publication Critical patent/KR20220110794A/ko
Application granted granted Critical
Publication of KR102930652B1 publication Critical patent/KR102930652B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57505—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875—Nucleoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020227022609A 2019-12-02 2020-12-02 바이오마커로서의 무세포 뉴클레오솜의 사용 Active KR102930652B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962942596P 2019-12-02 2019-12-02
US62/942,596 2019-12-02
US202063088408P 2020-10-06 2020-10-06
US63/088,408 2020-10-06
PCT/EP2020/084328 WO2021110776A1 (en) 2019-12-02 2020-12-02 Use of cell free nucleosomes as biomarkers

Publications (2)

Publication Number Publication Date
KR20220110794A KR20220110794A (ko) 2022-08-09
KR102930652B1 true KR102930652B1 (ko) 2026-02-25

Family

ID=73698838

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227022609A Active KR102930652B1 (ko) 2019-12-02 2020-12-02 바이오마커로서의 무세포 뉴클레오솜의 사용

Country Status (15)

Country Link
US (1) US20230003735A1 (https=)
EP (2) EP4435431A3 (https=)
JP (2) JP7693670B2 (https=)
KR (1) KR102930652B1 (https=)
CN (1) CN114829939B (https=)
AU (1) AU2020395504A1 (https=)
BR (1) BR112022010774A2 (https=)
CA (1) CA3163181A1 (https=)
ES (1) ES2988371T3 (https=)
IL (1) IL293342B1 (https=)
MX (1) MX2022006655A (https=)
PL (1) PL4070111T3 (https=)
TW (1) TWI902730B (https=)
WO (1) WO2021110776A1 (https=)
ZA (1) ZA202205916B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2820129A1 (en) * 2012-03-02 2015-01-07 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
EP3736344A1 (en) 2014-03-13 2020-11-11 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
JP2024542996A (ja) 2021-10-29 2024-11-19 ベルジアン ボリション エスアールエル 均一系免疫アッセイ法
GB202117799D0 (en) 2021-12-09 2022-01-26 Belgian Volition Srl Method for the detection of blood cancer
EP4490323A1 (en) 2022-03-11 2025-01-15 Belgian Volition SRL Differential diagnosis method
WO2024042210A1 (en) 2022-08-25 2024-02-29 Belgian Volition Srl Method for measuring cell free chromatin
EP4639173A1 (en) * 2022-12-19 2025-10-29 Belgian Volition SRL Calibration

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013030578A2 (en) 2011-09-01 2013-03-07 Singapore Volition Pte Limited Method for detecting nucleosomes
WO2013084002A2 (en) 2011-12-07 2013-06-13 Singapore Volition Pte Limited Method for detecting nucleosome adducts
US20140107039A1 (en) 2012-09-10 2014-04-17 The Rockefeller University Polycomb repressive complex 2 (prc2) inhibitors and uses thereof
WO2016067029A1 (en) 2014-10-29 2016-05-06 Singapore Volition Pte Limited Method for the enrichment of circulating tumor dna
WO2017001864A1 (en) 2015-07-01 2017-01-05 Singapore Volition Pte. Limited Use of cell-free nucleosomes as biomarkers in fecal samples
WO2017001863A1 (en) 2015-07-01 2017-01-05 Singapore Volition Pte. Limited Use of cell-free nucleosomes as biomarkers in sputum samples
WO2017068359A1 (en) 2015-10-21 2017-04-27 Belgian Volition Sprl Method for detecting nucleosomes containing histone modifications and variants
WO2019169263A1 (en) * 2018-03-01 2019-09-06 Epicypher, Inc. Quantification of nucleosome modifications using chemically-defined recombinant nucleosomes

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0319376D0 (en) 2003-08-18 2003-09-17 Chroma Therapeutics Ltd Histone modification detection
GB0413732D0 (en) * 2004-06-13 2004-07-21 Chroma Therapeutics Ltd Histone modification
ATE534908T1 (de) * 2009-08-03 2011-12-15 Universitaetsklinikum Freiburg Verfahren und verbindungen zur diagnose und behandlung von krebs
GB201115098D0 (en) 2011-09-01 2011-10-19 Belgian Volition Sa Method for detecting nucleosomes containing histone variants
GB201115095D0 (en) 2011-09-01 2011-10-19 Singapore Volition Pte Ltd Method for detecting nucleosomes containing nucleotides
EP2820129A1 (en) * 2012-03-02 2015-01-07 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
GB201518665D0 (en) * 2015-10-21 2015-12-02 Singapore Volition Pte Ltd Method for enrichment of cell free nucleosomes

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013030578A2 (en) 2011-09-01 2013-03-07 Singapore Volition Pte Limited Method for detecting nucleosomes
WO2013084002A2 (en) 2011-12-07 2013-06-13 Singapore Volition Pte Limited Method for detecting nucleosome adducts
US20140107039A1 (en) 2012-09-10 2014-04-17 The Rockefeller University Polycomb repressive complex 2 (prc2) inhibitors and uses thereof
WO2016067029A1 (en) 2014-10-29 2016-05-06 Singapore Volition Pte Limited Method for the enrichment of circulating tumor dna
WO2017001864A1 (en) 2015-07-01 2017-01-05 Singapore Volition Pte. Limited Use of cell-free nucleosomes as biomarkers in fecal samples
WO2017001863A1 (en) 2015-07-01 2017-01-05 Singapore Volition Pte. Limited Use of cell-free nucleosomes as biomarkers in sputum samples
WO2017068359A1 (en) 2015-10-21 2017-04-27 Belgian Volition Sprl Method for detecting nucleosomes containing histone modifications and variants
JP2018536849A (ja) * 2015-10-21 2018-12-13 ベルジアン ボリション エスピーアールエル ヒストン修飾及びバリアントを含むヌクレオソームを検出するための方法
WO2019169263A1 (en) * 2018-03-01 2019-09-06 Epicypher, Inc. Quantification of nucleosome modifications using chemically-defined recombinant nucleosomes

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
Beatriz Sanchez Correa et al., Cytokine, 2013.01.26., vol 61, no 3, pp 885-891.
Boheng Li et al, 2019.11.21., Journal of Hematology & Oncology, vol 12, no 1, XP055769518.
Heidi Schwarzenbach et al, 2011.05.12., vol 11, no 6, pp 426-437.
Herranz Michel et al, 2007.01.01., vol 361, pp 25-62.
M. T. Mccabe et al, 2012.02.21., Proceedings of The National Academy of Science, vol 109, no 8, pp 2989-2994.
Stefan Holdenrieder et al, 2001.03.20., International Journal of Cancer, vol 95, no 2, pp 114-120.
Stefan Holdenrieder et al, 2008.08.01., Annals of the New York Academy of Science, vol 1137, no 1, pp 180-189.

Also Published As

Publication number Publication date
EP4070111A1 (en) 2022-10-12
MX2022006655A (es) 2022-09-07
TW202134654A (zh) 2021-09-16
IL293342B1 (en) 2026-01-01
AU2020395504A1 (en) 2022-06-23
ES2988371T3 (es) 2024-11-20
JP7693670B2 (ja) 2025-06-17
CA3163181A1 (en) 2021-06-10
US20230003735A1 (en) 2023-01-05
EP4070111B1 (en) 2024-08-21
BR112022010774A2 (pt) 2022-08-23
KR20220110794A (ko) 2022-08-09
JP2025124845A (ja) 2025-08-26
JP2023503379A (ja) 2023-01-27
PL4070111T3 (pl) 2025-02-03
EP4435431A3 (en) 2024-10-16
EP4435431A2 (en) 2024-09-25
CN114829939B (zh) 2025-10-21
CN114829939A (zh) 2022-07-29
IL293342A (en) 2022-07-01
WO2021110776A1 (en) 2021-06-10
TWI902730B (zh) 2025-11-01
ZA202205916B (en) 2024-09-25
EP4070111C0 (en) 2024-08-21

Similar Documents

Publication Publication Date Title
KR102930652B1 (ko) 바이오마커로서의 무세포 뉴클레오솜의 사용
KR102442803B1 (ko) 결장직장암에 대한 복합 테스트
US20240019432A1 (en) Diagnostic method for multiple sclerosis
EP3963330B1 (en) Method for the detection of prostate cancer
US20240077487A1 (en) Method for the detection of lung cancer
EP3963331B1 (en) Method for the detection of cancer
HK40085725B (en) Use of cell free nucleosomes as biomarkers
HK40085725A (en) Use of cell free nucleosomes as biomarkers
EA047224B1 (ru) Применение бесклеточных нуклеосом в качестве биомаркеров
WO2024240939A1 (en) Use of cell free nucleosomes as biomarkers
US20250044291A1 (en) Method for the detection of blood cancer
WO2024223947A1 (en) Use of cell free nucleosomes as biomarkers of carcinomas
AU2023251199A1 (en) Method for transplant organ health assessment

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)